文献库搜索 | GeneLibs

Kamath(V),Pai(V),Bhat(B),K S(C),Nayak(PG),... Curr Top Med Chem 2026-08-03

...BRCA1/2 mutations, where further failure of DNA repair results in cell sensitization. Building on the concept of synthet...

Lai(E),Pierantoni(F),Zampiva(I),Bimbatti(D... Cancers (Basel) 2026-07-25

...BRCA1 (1.39%) being the most common alterations. A family history of breast, ovarian, or prostate cancer strongly predic...

Markowska(A),Wolski(H),de Mezer(M) Int J Mol Sci 2026-07-25

...BRCA1 carriers, but the evidence remains exploratory. In breast cancer, intratumoral bacteria may shape the immune micro...

Dos Santos(ES),Cicilini(AL),Simões(MFE),Ba... Int J Mol Sci 2026-07-28

Poly(ADP-ribose) polymerase inhibitors (PARPis) have demonstrated remarkable efficacy in tumors carrying BRCA1/2 pathoge...

Abinawanto,Sophian(A) Environ Mol Mutagen 2026-06-00

...BRCA1/2-mutant tumors. Despite initial efficacy, resistance inevitably emerges, limiting long-term clinical benefit. Thi...

Abdel-Razeq(H),Bani Hani(H),Alafeef(S),Tam... Front Oncol None

...BRCA1 P/LP variants were identified. Germline P/LP variants are common in young male patients with cancer, particularly ...

Gao(J),Wang(S),Huang(A),Wang(H),Xiao(Z) AME Case Rep None

...BRCA1 mutation. After completion of multidisciplinary neoadjuvant systemic therapy, the patient underwent E-NSM with imm...

Steenbock(O),Rieger(C),Heidenreich(J),Paff... Urol Int 2026-08-13

...BRCA1/2, CDK12, CTNNB1, DLL3, ETS family, FOXA1, FOXO1, MED12, PIK3CA, PTEN, RAD51C, TP53, Wnt-Pathway). Since 2023, we ...

Kapoor(A),Uthale(S),Chain(A),Rungta(A),Ano... JCO Glob Oncol 2026-08-00

...BRCA1/2, potentially underidentifying patients with other HRR gene variants who could benefit from targeted therapies. A...

Kamau(K),Byrne(L),Goradia(R),Sundi(D),Meng... Eur Urol Oncol 2026-08-13

...BRCA1, BRCA2, and ATM. Very small cohorts of patients with UC and LS or a DDR variant responded well to immune checkpoin...